S. L. Maude, Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia, N Engl J Med, vol.378, pp.439-448, 2018.

A. J. Kansagra, Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy, Biology of Blood and Marrow Transplantation, vol.25, pp.76-85, 2019.

R. A. Gardner, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, vol.129, pp.3322-3331, 2017.

E. J. Orlando, Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia, Nat Med, vol.24, pp.1504-1506, 2018.

J. Fischer, CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis, Journal of Immunotherapy, vol.40, pp.187-195, 2017.

M. Asnani, Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19, Leukemia, 2019.

E. Sotillo, Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy, Cancer Discovery, vol.5, pp.1282-1295, 2015.

M. Stoeckius, Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics, Genome Biol, vol.19, p.224, 2018.

G. X. Zheng, Massively parallel digital transcriptional profiling of single cells, Nat Commun, vol.8, p.14049, 2017.

A. Butler, P. Hoffman, P. Smibert, E. Papalexi, and R. Satija, Integrating single-cell transcriptomic data across different conditions, technologies, and species, Nat. Biotechnol, vol.36, pp.411-420, 2018.

G. Narla, KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer, Science, vol.294, pp.2563-2566, 2001.

M. Tetreault, Y. Yang, and J. P. Katz, Krüppel-like factors in cancer, Nat Rev Cancer, vol.13, pp.701-713, 2013.

S. A. Grupp, Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia, N Engl J Med, vol.368, pp.1509-1518, 2013.

J. A. Van-buggenum, A covalent and cleavable antibody-DNA conjugation strategy for sensitive protein detection via immuno-PCR, Sci Rep, vol.6, p.22675, 2016.

T. Stuart, Comprehensive Integration of Single-Cell Data, Cell, vol.177, 1888.

G. X. Zheng, Massively parallel digital transcriptional profiling of single cells, Nat Commun, vol.8, p.14049, 2017.

A. Butler, P. Hoffman, P. Smibert, E. Papalexi, and R. Satija, Integrating single-cell transcriptomic data across different conditions, technologies, and species, Nat. Biotechnol, vol.36, pp.411-420, 2018.

S. Aibar, SCENIC: single-cell regulatory network inference and clustering, Nat. Methods, vol.14, pp.1083-1086, 2017.

, où de nombreux paramètres influencent à la fois l'efficacité, la tolérance, l'accessibilité ou le prix du médicament. Cette nouvelle thérapie s'avère être une approche efficace pour traiter les patients atteints de LAL-B réfractaires à la thérapie conventionnelle. Cependant, environ 35% des patients rechutent et plus de la moitié de ces rechutes sont CD19-négatives. Des études antérieures ont examiné le mécanisme d'inhibition de l'expression du CD19, mais à ce jour, Les CAR-T cells ciblant l'antigène CD19 sont des médicaments d'un genre nouveau

, Nous avons ainsi abordé cette question et démontré que de rares clones de LAL-B

, ce qui implique que la rechute résulterait d'une sélection Darwinienne de rares sous-clones préexistants, et non du traitement par les cellules CAR-T en soi. Ainsi, l'avancée majeure de notre étude est que nous pouvons détecter RÉFÉRENCES BIBLIOGRAPHIQUES 1. Immunothérapie : mode d'action -Thérapies ciblées et immunothérapie spécifique | Institut National Du Cancer, CD19-négatifs étaient présents avant CAR-T cells

A. Hoos, Development of immuno-oncology drugs -from CTLA4 to PD1 to the next generations, Nat. Rev. Drug Discov, vol.15, issue.4, pp.235-247, 2016.

M. B. May and A. Glode, Blinatumomab: A novel, bispecific, T-cell engaging antibody, Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm, vol.73, issue.1, pp.6-13, 2016.

S. A. Rosenberg, P. Spiess, and R. Lafreniere, A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes, Science, vol.233, issue.4770, pp.1318-1321, 1986.

R. A. Morgan, M. E. Dudley, and J. R. Wunderlich, Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes, Science, vol.314, issue.5796, pp.126-129, 2006.

L. A. Johnson, R. A. Morgan, and M. E. Dudley, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, vol.114, issue.3, pp.535-546, 2009.

R. A. Morgan, N. Chinnasamy, and D. Abate-daga, Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy, J. Immunother. Hagerstown Md, vol.36, issue.2, pp.133-151, 1997.

M. Aleksic, N. Liddy, and P. E. Molloy, Different affinity windows for virus and cancerspecific T-cell receptors: implications for therapeutic strategies, Eur. J. Immunol, vol.42, issue.12, pp.3174-3179, 2012.

D. L. Porter, W. Hwang, and N. V. Frey, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci. Transl. Med, vol.7, issue.303, pp.303-139, 2015.

S. L. Maude, T. W. Laetsch, and J. Buechner, Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia, N. Engl. J. Med, vol.378, issue.5, pp.439-448, 2018.

R. A. Gardner, O. Finney, and C. Annesley, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, vol.129, issue.25, pp.3322-3331, 2017.

S. L. Maude, M. A. Pulsipher, and M. W. Boyer, Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis, Blood, vol.128, issue.22, pp.2801-2801, 2016.

J. Galaine, Y. Godet, and O. Adotévi, Pour comprendre : l'activation lymphocytaire T, Bull. Cancer (Paris), vol.103, pp.127-131, 2016.

H. Dai, Y. Wang, X. Lu, and W. Han, Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy, JNCI J. Natl. Cancer Inst, vol.108, issue.7, 2016.

S. Makita, K. Yoshimura, and K. Tobinai, Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma, Cancer Sci, vol.108, issue.6, pp.1109-1118, 2017.

C. Zhang, J. Liu, J. F. Zhong, and X. Zhang, Engineering CAR-T cells, Biomark. Res, vol.5, issue.1, p.22, 2017.

H. J. Jackson, S. Rafiq, and R. J. Brentjens, Driving CAR T-cells forward, Nat. Rev. Clin. Oncol, vol.13, issue.6, pp.370-383, 2016.

J. Zhao, Q. Lin, Y. Song, and D. Liu, Universal CARs, universal T cells, and universal CAR T cells, J. Hematol. Oncol.J Hematol Oncol, vol.11, issue.1, p.132, 2018.

M. Dourthe, K. Yakouben, and D. Chaillou, CAR-T cells : indications actuelles en pédiatrie et perspectives de développement, Bull. Cancer (Paris), vol.105, pp.147-157, 2018.

G. Gross, T. Waks, and Z. Eshhar, Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity, Proc. Natl. Acad. Sci, vol.86, issue.24, pp.10024-10028, 1989.

Z. Eshhar, T. Waks, G. Gross, and D. G. Schindler, Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors, Proc. Natl. Acad. Sci. U. S. A, vol.90, issue.2, pp.720-724, 1993.

Z. Wang, Y. Guo, and W. Han, Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment, Protein Cell, vol.8, issue.12, pp.896-925, 2017.

M. Rubio, J. Galaine, C. Borg, É. Daguindau, and . Biologie, concepts et principes des CAR-T cells, vol.105, pp.135-146, 2018.

T. Brocker and K. Karjalainen, Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes, J. Exp. Med, vol.181, issue.5, pp.1653-1659, 1995.

T. Brocker, Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells, Blood, vol.96, issue.5, pp.1999-2001, 2000.

S. Van-der-stegen, M. Hamieh, and M. Sadelain, The pharmacology of second-generation chimeric antigen receptors, Nat. Rev. Drug Discov, vol.14, issue.7, pp.499-509, 2015.

J. Maher, R. J. Brentjens, G. Gunset, I. Rivière, and M. Sadelain, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR? /CD28 receptor, Nat. Biotechnol, vol.20, issue.1, pp.70-75, 2002.

C. Imai, K. Mihara, and M. Andreansky, Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia, Leukemia, vol.18, issue.4, pp.676-684, 2004.

Z. Zhao, M. Condomines, and S. Van-der-stegen, Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells, Cancer Cell, vol.28, issue.4, pp.415-428, 2015.

A. A. Hombach and H. Abken, Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling, Int. J. Cancer, vol.129, issue.12, pp.2935-2944, 2011.

E. Kymriah, R. Disponible, and . Sur,

E. Yescarta, R. Disponible, and . Sur,

M. Chmielewski and H. Abken, TRUCKs: the fourth generation of CARs, Expert Opin. Biol. Ther, vol.15, issue.8, pp.1145-1154, 2015.

M. Chmielewski, C. Kopecky, A. A. Hombach, and H. Abken, IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression, Cancer Res, vol.71, issue.17, pp.5697-5706, 2011.

, Immunothérapies spécifiques dans le traitement des cancers : rapport et une synthèse

B. L. Levine, Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells, Cancer Gene Ther, vol.22, issue.2, pp.79-84, 2015.

M. Sadelain, I. Rivière, and S. Riddell, Therapeutic T cell engineering, Nature, vol.545, issue.7655, pp.423-431, 2017.

D. Sommermeyer, M. Hudecek, and P. L. Kosasih, Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo, Leukemia, vol.30, issue.2, pp.492-500, 2016.

W. S. Hu and V. K. Pathak, Design of retroviral vectors and helper cells for gene therapy, Pharmacol. Rev, vol.52, issue.4, pp.493-511, 2000.

M. C. Milone, O. Doherty, and U. , Clinical use of lentiviral vectors, Leukemia, vol.32, issue.7, pp.1529-1541, 2018.

C. Jin, G. Fotaki, and M. Ramachandran, Safe engineering of CAR T cells for adoptive cell therapy of cancer using long term episomal gene transfer, EMBO Mol. Med, vol.8, issue.7, pp.702-711, 2016.

D. C. Bishop, N. Xu, and B. Tse, PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts, Mol. Ther, vol.26, issue.8, pp.1883-1895, 2018.

H. Singh, P. R. Manuri, and S. Olivares, Redirecting Specificity of T-Cell Populations For CD19 Using the Sleeping Beauty System, Cancer Res, vol.68, issue.8, pp.2961-2971, 2008.

T. T. Smith, S. B. Stephan, and H. F. Moffett, In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers, Nat. Nanotechnol, vol.12, issue.8, pp.813-820, 2017.

R. Somerville and M. E. Dudley, Bioreactors get personal, OncoImmunology, vol.1, issue.8, pp.1435-1437, 2012.

I. Yakoub-agha, C. Chabannon, and P. Bader, Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE), Haematologica, vol.105, issue.2, pp.297-316, 2020.
URL : https://hal.archives-ouvertes.fr/hal-02485853

Y. Yang, E. Jacoby, and T. J. Fry, Challenges and opportunities of allogeneic donor-derived CAR T cells, Curr. Opin. Hematol, vol.22, issue.6, pp.509-515, 2015.

W. Qasim, H. Zhan, and S. Samarasinghe, Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Sci. Transl. Med, vol.9, issue.374, p.2013, 2017.

S. Vairy, J. L. Garcia, P. Teira, and H. Bittencourt, CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia, Drug Des. Devel. Ther, vol.12, pp.3885-3898, 2018.

T. J. Fry, N. N. Shah, and R. J. Orentas, CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Nat. Med, vol.24, issue.1, pp.20-28, 2018.

J. Edwards and G. Cambridge, B-cell targeting in rheumatoid arthritis and other autoimmune diseases, Nat. Rev. Immunol, vol.6, issue.5, pp.394-403, 2006.

E. Campo, S. H. Swerdlow, and N. L. Harris, The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5032, 2011.

T. Terwilliger and M. Abdul-hay, Acute lymphoblastic leukemia: a comprehensive review and 2017 update, Blood Cancer J, vol.7, issue.6, pp.577-577, 2017.

P. Brown, H. Inaba, and C. Annesley, Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology, J. Natl. Compr. Cancer Netw. JNCCN, vol.18, issue.1, pp.81-112, 2020.

, Orphanet: Leucémie lymphoblastique aiguë

. Société-française-d'hématologie and . Hématologie, Chapitre 4: Item 312 -UE 9 Leucémies aiguës. 3ème édition, 2018.

M. C. Bene, G. Castoldi, and W. Knapp, Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL), Leukemia, vol.9, issue.10, pp.1783-1786, 1995.

D. A. Arber, A. Orazi, and R. Hasserjian, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, issue.20, pp.2391-2405, 2016.

S. P. Hunger and C. G. Mullighan, Acute Lymphoblastic Leukemia in Children, N. Engl. J. Med, vol.373, issue.16, pp.1541-1552, 2015.

S. L. Cooper and P. A. Brown, Treatment of Pediatric Acute Lymphoblastic Leukemia, Pediatr. Clin. North Am, vol.62, issue.1, pp.61-73, 2015.

, NCCN Clinical Practice Guidelines in Oncology. Acute lymphoblastic Leukemia, 2018.

P. S. Gaynon, Childhood acute lymphoblastic leukaemia and relapse, Br. J. Haematol, vol.131, issue.5, pp.579-587, 2005.

. Has, . Avis, and . Kymriah,

A. J. Kansagra, N. V. Frey, and M. Bar, Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy, Biol. Blood Marrow Transplant, vol.25, issue.3, pp.76-85, 2019.

D. W. Lee, J. N. Kochenderfer, and M. Stetler-stevenson, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, The Lancet, vol.385, issue.9967, pp.517-528, 2015.

D. W. Lee, M. Stetler-stevenson, and C. M. Yuan, Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation, Blood, vol.128, issue.22, pp.218-218, 2016.

S. A. Grupp, S. L. Maude, and S. Rives, Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia, Blood, vol.132, pp.895-895, 2018.

K. J. Curran, S. P. Margossian, and N. A. Kernan, Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL, Blood, vol.134, issue.26, pp.2361-2368, 2019.

, Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients -Full Text View -ClinicalTrials.gov

, Tisagenlecleucel Versus Blinatumomab or Inotuzumab for Adult Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia: A Randomized Open Label, Multicenter, Phase III Trial. clinicaltrials.gov, Novartis Pharmaceuticals, 2020.

J. N. Brudno and J. N. Kochenderfer, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, vol.127, issue.26, pp.3321-3330, 2016.

S. L. Maude, N. Frey, and P. A. Shaw, Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia, N. Engl. J. Med, vol.371, issue.16, pp.1507-1517, 2014.

N. Singh, Y. G. Lee, and O. Shestova, Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction, Cancer Discov, vol.10, issue.4, pp.552-567, 2020.

X. Xu, Q. Sun, and X. Liang, Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies, Front. Immunol, vol.10, p.2664, 2019.

J. Cao, H. Cheng, and M. Shi, Humanized CD19-specific chimeric antigen-receptor Tcells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia, Leukemia, vol.33, issue.11, pp.2751-2753, 2019.

S. L. Maude, D. M. Barrett, and S. R. Rheingold, Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia, Blood, vol.128, issue.22, pp.217-217, 2016.

R. Gardner, O. Finney, and H. Brakke, Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy, Blood, vol.132, pp.4022-4022, 2018.

E. J. Orlando, X. Han, and C. Tribouley, Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia, Nat. Med, vol.24, issue.10, pp.1504-1506, 2018.

E. Sotillo, D. M. Barrett, and K. L. Black, Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy, Cancer Discov, vol.5, issue.12, pp.1282-1295, 2015.

D. M. Barrett, A. E. Seif, and C. Carpenito, Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling, Blood, vol.118, issue.15, pp.112-117, 2011.

B. Wang and N. Lee, Aberrant RNA Splicing in Cancer and Drug Resistance, Cancers, vol.10, issue.11, p.458, 2018.

J. Fischer, C. Paret, E. Malki, and K. ,

, Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis, J. Immunother, vol.40, issue.5, pp.187-195, 2017.

M. Asnani, K. E. Hayer, and A. S. Naqvi, Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19, Leukemia, 2019.

S. A. Grupp, M. Kalos, and D. Barrett, Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia, N. Engl. J. Med, vol.368, issue.16, pp.1509-1518, 2013.

R. Gardner, D. Wu, and S. Cherian, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy, Blood, vol.127, issue.20, pp.2406-2410, 2016.

D. W. Lee, R. Gardner, and D. L. Porter, Current concepts in the diagnosis and management of cytokine release syndrome, Blood, vol.124, issue.2, pp.188-195, 2014.

A. Cohen, D. Petsche, T. Grunberger, and M. H. Freedman, Interleukin 6 induces myeloid differentiation of a human biphenotypic leukemic cell line, Leuk. Res, vol.16, issue.8, pp.751-760, 1992.

D. Reynaud, E. Pietras, and K. Barry-holson, IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development, Cancer Cell, vol.20, issue.5, pp.661-673, 2011.

F. Perna and M. Sadelain, Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy. Transl, Cancer Res, vol.5, issue.S2, pp.221-225, 2016.

O. M. Lucero, K. Parker, and T. Funk, Phenotype switch in acute lymphoblastic leukaemia associated with 3 years of persistent CAR T cell directed-CD19 selective pressure, Br. J. Haematol, vol.186, issue.2, pp.333-336, 2019.

M. Hamieh, A. Dobrin, and A. Cabriolu, CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape, Nature, vol.568, issue.7750, pp.112-116, 2019.

M. Ruella, J. Xu, and D. M. Barrett, Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell, Nat. Med, vol.24, issue.10, pp.1499-1503, 2018.

M. Stoeckius, C. Hafemeister, and W. Stephenson, Simultaneous epitope and transcriptome measurement in single cells, Nat. Methods, vol.14, issue.9, pp.865-868, 2017.

A. Butler, P. Hoffman, P. Smibert, E. Papalexi, and R. Satija, Integrating single-cell transcriptomic data across different conditions, technologies, and species, Nat. Biotechnol, vol.36, issue.5, pp.411-420, 2018.

, Index -Single Cell Gene Expression -Official 10x Genomics Support

J. Buggenum, . Van, J. P. Gerlach, and S. Tanis, Immuno-Detection by sequencing (IDseq) enables large-scale high-dimensional phenotyping in cells, p.158139, 2017.

, CITE-seq Hyper Antibody-Oligo Conjugation

, Index -Single Cell Immune Profiling -Official 10x Genomics Support

. Has, . Avis, and . Blincyto,

J. Pan, Q. Niu, and B. Deng, CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia, Leukemia, vol.33, issue.12, pp.2854-2866, 2019.

A. Grain, M. Dourthe, and A. Baruchel, CAR-T cells et leucémies aiguës lymphoblastiques : avancées et questionnements, Bull. Cancer (Paris), vol.107, issue.2, pp.234-243, 2020.

L. Schultz, K. Davis, C. Baggott, C. Chaudry, A. Marcy et al., Phase 1 study of CD19/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B cell acute lymphoblastic leuke-mia (ALL), Blood, vol.132, p.898, 2018.

M. Ruella, D. M. Barrett, and S. S. Kenderian, Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies, J. Clin. Invest, vol.126, issue.10, pp.3814-3826, 2016.

K. T. Roybal, L. J. Rupp, and L. Morsut, Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits, Cell, vol.164, issue.4, pp.770-779, 2016.

H. Qin, S. Ramakrishna, and S. Nguyen, Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22, Mol. Ther. Oncolytics, vol.11, pp.127-137, 2018.

Z. Grada, M. Hegde, and T. Byrd, A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy, Mol. Ther. -Nucleic Acids, vol.2, p.105, 2013.

A. Biondi, C. F. Magnani, S. Tettamanti, G. Gaipa, and E. Biagi, Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia, J. Autoimmun, vol.85, pp.141-152, 2017.

, CAR-T cells : des médicaments prometteurs, que la HAS réévaluera pour en confirmer le potentiel. Haute Autorité de santé